
Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia...
HyperlipoproteinemiaMetabolic SyndromeThe study is designed to evaluate the effect of Niacin/Laropiprant on postprandial lipoprotein metabolism, postprandial glucose metabolism, postprandial monocyte function, and postprandial biomarkers of endothelial dysfunction and inflammation.

IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents...
HIV InfectionsHyperlipidemiaTreatment of HIV with combination antiretroviral regimens frequently results in the suppression of HIV viral load, significant immune recovery, and delayed disease progression. However, treatment with these regimens, particularly protease inhibitors (PIs), has been associated with significant increases in cholesterol and triglycerides in HIV-infected adults and children. The purpose of this study was to evaluate the safety and effectiveness of escalating doses of atorvastatin, a FDA-approved drug which lowers cholesterol and triglyceride levels, in HIV-infected children receiving stable antiretroviral regimens.

MK0859 Dose-Ranging Study (0859-003)
HypercholesterolemiaMixed HyperlipemiaTo assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.

School-based Education and Screening Program With Lipid Screening as a Means to Identify Familial...
Familial HyperlipidemiaDetermination of FH status by genetic testing in school age children who have demonstrated elevated cholesterol on baseline screening.

PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin
HypertensionHyperlipidemiaThis is a Randomized, open-label, single-dose, 3-treatment, 3-period, 3-sequence crossover design.

Postprandial Lipemia and Glycemia Following a High-Fat Meal
HypercholesterolemiaPostprandial Hyperglycemia1 moreThe goal of this clinical trial is to determine the acute effects on postprandial lipemia and glycemia by supplementing a high-fat meal with either white button (WB) or shiitake (SH) mushroom powder in relatively healthy adults, aged 18 to 35.

Orlistat for the Treatment of Type I Hyperlipoproteinemia
Hyperlipoproteinemia Type IHypertriglyceridemiaPatients with Type I Hyperlipoproteinemia (T1HLP) have a rare form of hypertriglyceridemia marked by significant chylomicronemia and recurrent episodes of acute pancreatitis. T1HLP is caused by a deficiency of lipoprotein lipase or one of its cofactors. Many patients are a challenge to treat, as the only effective therapy available is an extremely low fat diet. This diet is exceedingly difficult to follow, and despite adherence, many patients still have chylomicronemia and develop acute pancreatitis. Specific Aim: To determine the efficacy of a gastric and pancreatic lipase inhibitor, Orlistat, in reducing serum triglyceride levels in patients with T1HLP.

A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin...
HypertensionHyperlipidemiaA Open-label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics and Safety between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin versus Co-administration of a Fixed Dose Combination of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects.

Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers
DiabetesHyperlipidemiaA randomized, open-label, single dose, crossover study to investigate the effect of food on the pharmacokinetics of JLP-1310 in healthy male volunteers.

Pharmacokinetic Drug-drug Interaction of CKD-330 and D086
HypertensionHyperlipidemiasThe purpose of the study is examining and comparing the pharmacokinetic drug interaction and safety of both single administration and combination administration of CKD-330 and D086 to healthy male subjects